Hematological oncology

Keyphrases

Publications

volume 42, number 3, 2024

Gabriela Forestieri, Joyce Marques de Almeida, Sara Napoli, Deborah Piffaretti, Chiara Tarantelli, Fangwen Zhang, Afua Adjeiwaa Mensah
Discovery Science highlights from the 17th International Conference on Malignant Lymphoma. Hematological oncology 42 (3) (2024)
Vittorio Ruggero Zilioli, Emanuele Cencini, Sonya De Lorenzo, Luca Pezzullo, Michele Merli, Flavia Rivellini, Cristina Muzi, Barbieri Emiliano, Luigi Marcheselli, Stefano Luminari
Real-life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience. Hematological oncology 42 (3) (2024)
Jessica Saddi, Amelia Barcellini, Manuel Gotti, Alessandro Mazzacane, Alessandra Tolva, Tanja Lazic, Luca Arcaini, Marco Zecca, Ester Orlandi, Andrea Riccardo Filippi
Future perspectives of radiation therapy for Hodgkin Lymphoma: Risk-adapted, response-adapted, and safer than before. Hematological oncology 42 (3) (2024)
Alessandra Iurlo, Fabio Serpenti, Roberta Zanotti, Patrizia Bonadonna, Ilaria Tanasi, Lara Crosera, Chiara Elena, Francesco Mannelli, Francesca Crupi, Cristina Papayannidis, Chiara Sartor, Simona Soverini, Michela Rondoni, Cristina Eller-Vainicher, Valerio Pravettoni, Federica Rivolta, Silvia Alberti Violetti, Giorgio Alberto Croci, Anna Chiara Migliorini, Niccolo' Bolli, Diana Giannarelli, Federica Irene Grifoni
Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis. Hematological oncology 42 (3) (2024)
Kaitlin Annunzio, Subodh Bhatta, Walter Hanel, Qiuhong Zhao, Mackenzie Owen, Havi Rosen, Timothy J Voorhees, David A Bond, Yazeed Sawalha, Audrey M Sigmund, Lapo Alinari, Robert A Baiocchi, Kami J Maddocks, Daniel M Jones, Beth Christian, Narendranath Epperla
Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients. Hematological oncology 42 (3) (2024)
Sudhir Manda, Bertrand M Anz, Christopher Benton, E Randolph Broun, Habte A Yimer, John S Renshaw, George Geils, Jesus G Berdeja, Jose Cruz, Jason M Melear, Suzanne Fanning, Luke Fletcher, Yukun Li, Yinghui Duan, Michael E Werner, Jalaja Potluri, Madhavi V Pai, William B Donnellan
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia. Hematological oncology 42 (3) (2024)
Alessandra Iurlo, Fabio Serpenti, Roberta Zanotti, Patrizia Bonadonna, Ilaria Tanasi, Lara Crosera, Chiara Elena, Francesco Mannelli, Francesca Crupi, Cristina Papayannidis, Chiara Sartor, Simona Soverini, Michela Rondoni, Cristina Eller-Vainicher, Valerio Pravettoni, Federica Rivolta, Silvia Alberti Violetti, Giorgio Alberto Croci, Anna Chiara Migliorini, Niccolo' Bolli, Diana Giannarelli, Federica Irene Grifoni
Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis. Hematological oncology 42 (3) (2024)
Jiangfang Feng, Yue Fei, Meng Gao, Xiangrui Meng, Dongfeng Zeng, Dehui Zou, Haige Ye, Yun Liang, Xiuhua Sun, Rong Liang, Hui Zhou, Xianhuo Wang, Huilai Zhang
Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma. Hematological oncology 42 (3) (2024)
Jessica Saddi, Amelia Barcellini, Manuel Gotti, Alessandro Mazzacane, Alessandra Tolva, Tanja Lazic, Luca Arcaini, Marco Zecca, Ester Orlandi, Andrea Riccardo Filippi
Future perspectives of radiation therapy for Hodgkin Lymphoma: Risk-adapted, response-adapted, and safer than before. Hematological oncology 42 (3) (2024)
Vittorio Ruggero Zilioli, Emanuele Cencini, Sonya De Lorenzo, Luca Pezzullo, Michele Merli, Flavia Rivellini, Cristina Muzi, Barbieri Emiliano, Luigi Marcheselli, Stefano Luminari
Real-life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience. Hematological oncology 42 (3) (2024)
José Carlos Jaime-Pérez, Marcela Hernández-Coronado, Mariana González-Treviño, Renata V Barragán-Longoria, Eugenia M Ramos-Dávila, Guillermo José Ruiz Argüelles
Outcomes after treating advanced mantle cell lymphoma in a low-income group at a Latin American center: The role of outpatient hematopoietic stem cell transplantation. Hematological oncology 42 (3) (2024)
Anna Panovská, Pavel Žák, Tereza Jurková, Tomáš Arpáš, Yvona Brychtová, Alžběta Vašíková, Viera Hrabčáková, Adéla Prchlíková, Martina Filipová, Michael Doubek
Real-world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL-CLLEAR study. Hematological oncology 42 (3) (2024)
Gabriela Forestieri, Joyce Marques de Almeida, Sara Napoli, Deborah Piffaretti, Chiara Tarantelli, Fangwen Zhang, Afua Adjeiwaa Mensah
Discovery Science highlights from the 17th International Conference on Malignant Lymphoma. Hematological oncology 42 (3) (2024)
Takashi Watanabe, Yoshihiro Matsuno, Masashi Wakabayashi, Dai Maruyama, Kazuhito Yamamoto, Nobuko Kubota, Kazuyuki Shimada, Kohsuke Asagoe, Motoko Yamaguchi, Kiyoshi Ando, Michinori Ogura, Junya Kuroda, Youko Suehiro, Kunihiro Tsukasaki, Kensei Tobinai, Hirokazu Nagai
Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203. Hematological oncology 42 (3) (2024)
Xin-Yu Li, Shaofen Lin, Ning Liao, Huirong Mai, Xingjiang Long, Lili Liu, Beiyan Wu, Qiwen Chen, Qian Kong, Xianling Kong, Lixia Liu, Jia-Yue Qin, Jianpei Fang, Dunhua Zhou
The RAS-signaling-pathway-mutation-related prognosis in B-cell acute lymphoblastic leukemia: A report from South China children's leukemia group. Hematological oncology 42 (3) (2024)
Gabriela Forestieri, Joyce Marques de Almeida, Sara Napoli, Deborah Piffaretti, Chiara Tarantelli, Fangwen Zhang, Afua Adjeiwaa Mensah
Discovery Science highlights from the 17th International Conference on Malignant Lymphoma. Hematological oncology 42 (3) (2024)
Maria Livia Del Giudice, Sara Galimberti, Gabriele Buda
Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis. Hematological oncology 42 (3) (2024)
Gabriela Forestieri, Joyce Marques de Almeida, Sara Napoli, Deborah Piffaretti, Chiara Tarantelli, Fangwen Zhang, Afua Adjeiwaa Mensah
Discovery Science highlights from the 17th International Conference on Malignant Lymphoma. Hematological oncology 42 (3) (2024)
Vittorio Ruggero Zilioli, Emanuele Cencini, Sonya De Lorenzo, Luca Pezzullo, Michele Merli, Flavia Rivellini, Cristina Muzi, Barbieri Emiliano, Luigi Marcheselli, Stefano Luminari
Real-life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience. Hematological oncology 42 (3) (2024)
María Turos-Cabal, Ana M Sánchez-Sánchez, Noelia Puente-Moncada, Federico Herrera, Isaac Antolín, Carmen Rodríguez, Vanesa Martin
FLT3-ITD regulation of the endoplasmic reticulum functions in acute myeloid leukemia. Hematological oncology 42 (3) (2024)

volume 42, number 4, 2024

Xiaohui Suo, Zheng Fang, Dongmei Wang, Liyun Zhao, Jie Liu, Hong Li, Xiaojun Ma, Congcong Zhang, Xuemei Zhao, Rui Shi, Yan Wu, Zongjiu Jiao, Jiaojie Song, Ling Zhang, Ling Li, Suping Zhang, Xinxiao Lu, Linyu Yuan, Sifeng Gao, Jilei Zhang, Kaiqi Liu, Xingli Zhao, Guanchen Bai, Yingchang Mi
Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial. Hematological oncology 42 (4) (2024)
Danai Dima, Utkarsh Goel, Aishwarya Sannareddy, Nnaemeka Ibeh, Fauzia Ullah, Aimaz Afrough, Sandra Mazzoni, Ali Mehdi, Joslyn Rudoni, Shahzad Raza, Nicole De Simone, Louis Williams, Adeel M Khan, Aliya Rashid, Mikhaila Rice, Kristin Ricci, Christy Samaras, Jason Valent, Larry D Anderson, Faiz Anwar, Gurbakhash Kaur, Jack Khouri
Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy. Hematological oncology 42 (4) (2024)
Kenji Ishitsuka, Tomoharu Yasukawa, Yukie Tsuji
Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4-positive peripheral T-cell lymphoma and relapsed or refractory cutaneous T-cell lymphoma: A post-marketing surveillance in Japan. Hematological oncology 42 (4) (2024)
Chunxiang Xiang, Limin Gao, Qing Tao, Zihang Chen, Sha Zhao, Weiping Liu
TET2 regulates extranodal NK/T cell lymphoma progression through regulation of DNA methylation. Hematological oncology 42 (4) (2024)
Danai Dima, Utkarsh Goel, Aishwarya Sannareddy, Nnaemeka Ibeh, Fauzia Ullah, Aimaz Afrough, Sandra Mazzoni, Ali Mehdi, Joslyn Rudoni, Shahzad Raza, Nicole De Simone, Louis Williams, Adeel M Khan, Aliya Rashid, Mikhaila Rice, Kristin Ricci, Christy Samaras, Jason Valent, Larry D Anderson, Faiz Anwar, Gurbakhash Kaur, Jack Khouri
Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy. Hematological oncology 42 (4) (2024)
Caroline Le Lan, Aurélien Belot, Camille Golfier, Bérénice Audin, Pierre Sesques, Adeline Bernier, Violaine Safar, Emmanuelle Ferrant, Anne Lazareth, Hélène Lequeu, Lionel Karlin, Dana Ghergus, Alizée Maarek, Guillaume Aussedat, Maryam Idlhaj, Gilles Andre Salles, Fanny Cherblanc, Emmanuel Bachy, Hervé Ghesquières
Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital. Hematological oncology 42 (4) (2024)
Danai Dima, Utkarsh Goel, Aishwarya Sannareddy, Nnaemeka Ibeh, Fauzia Ullah, Aimaz Afrough, Sandra Mazzoni, Ali Mehdi, Joslyn Rudoni, Shahzad Raza, Nicole De Simone, Louis Williams, Adeel M Khan, Aliya Rashid, Mikhaila Rice, Kristin Ricci, Christy Samaras, Jason Valent, Larry D Anderson, Faiz Anwar, Gurbakhash Kaur, Jack Khouri
Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy. Hematological oncology 42 (4) (2024)
Hanyin Wang, Shulan Tian, Charla R Secreto, Sutapa Sinha, Min Shi, Timothy Call, Yucai Wang, Sameer A Parikh, Saad Sirop Kenderian, Rong He, Jose F Leis, Daniel L VanDyke, Eric W Klee, Susan L Slager, Esteban Braggio, Huihuang Yan, Wei Ding
Clonal dynamics of Richter transformation in chronic lymphocytic leukemia. Hematological oncology 42 (4) (2024)
Hana Dostálová, Vladimir Kryštof
Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib. Hematological oncology 42 (4) (2024)
Enrica Antonia Martino, Salvatore Palmieri, Monica Galli, Daniele Derudas, Roberto Mina, Roberta Della Pepa, Renato Zambello, Ernesto Vigna, Antonella Bruzzese, Silvia Mangiacavalli, Elena Zamagni, Catello Califano, Maurizio Musso, Concetta Conticello, Claudio Cerchione, Giuseppe Mele, Nicola Di Renzo, Massimo Offidani, Giuseppe Tarantini, Gloria Margiotta Casaluci, Angela Rago, Roberto Ria, Giuseppina Uccello, Gregorio Barilà, Gaetano Palumbo, Loredana Pettine, Iolanda Donatella Vincelli, Marino Brunori, Fabrizio Accardi, Valeria Amico, Angela Amendola, Raffaele Fontana, Velia Bongarzoni, Bernardo Rossini, Emilia Cotzia, Alessandro Gozzetti, Rita Rizzi, Nicola Sgherza, Giovanni Reddiconto, Antonio Maroccia, Luca Franceschini, Giuseppe Bertuglia, Davide Nappi, Emiliano Barbieri, Barbara Gamberi, Maria Teresa Petrucci, Francesco Di Raimondo, Antonino Neri, Fortunato Morabito, Pellegrino Musto, Massimo Gentile
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials. Hematological oncology 42 (4) (2024)
Kenji Ishitsuka, Tomoharu Yasukawa, Yukie Tsuji
Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4-positive peripheral T-cell lymphoma and relapsed or refractory cutaneous T-cell lymphoma: A post-marketing surveillance in Japan. Hematological oncology 42 (4) (2024)
Andrealuna Ucciero, Giuseppe Traversa, Alessia Pisterna, Valeria Cardinali, Sofia Sciabolacci, Antonella Poloni, Debora Capelli, Gianluca Gaidano, Andrea Patriarca, Monia Lunghi
Prescription patterns of venetoclax in acute myeloid leukemia. Hematological oncology 42 (4) (2024)
Enrica Antonia Martino, Salvatore Palmieri, Monica Galli, Daniele Derudas, Roberto Mina, Roberta Della Pepa, Renato Zambello, Ernesto Vigna, Antonella Bruzzese, Silvia Mangiacavalli, Elena Zamagni, Catello Califano, Maurizio Musso, Concetta Conticello, Claudio Cerchione, Giuseppe Mele, Nicola Di Renzo, Massimo Offidani, Giuseppe Tarantini, Gloria Margiotta Casaluci, Angela Rago, Roberto Ria, Giuseppina Uccello, Gregorio Barilà, Gaetano Palumbo, Loredana Pettine, Iolanda Donatella Vincelli, Marino Brunori, Fabrizio Accardi, Valeria Amico, Angela Amendola, Raffaele Fontana, Velia Bongarzoni, Bernardo Rossini, Emilia Cotzia, Alessandro Gozzetti, Rita Rizzi, Nicola Sgherza, Giovanni Reddiconto, Antonio Maroccia, Luca Franceschini, Giuseppe Bertuglia, Davide Nappi, Emiliano Barbieri, Barbara Gamberi, Maria Teresa Petrucci, Francesco Di Raimondo, Antonino Neri, Fortunato Morabito, Pellegrino Musto, Massimo Gentile
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials. Hematological oncology 42 (4) (2024)
Xiaohui Wang, Hengqi Liu, Yue Fei, Zheng Song, Xiangrui Meng, Jingwei Yu, Xia Liu, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Xianhuo Wang, Huilai Zhang
Metabolic pathway-based subtyping reveals distinct microenvironmental states associated with diffuse large B-cell lymphoma outcomes. Hematological oncology 42 (4) (2024)
Claudia Bellofiore, Pietro Benvenuti, Roberto Mina, Marco Basset, Andrea Foli, Martina Nanci, Mario Nuvolone, Gianluigi Guida, Andrea Attanasio, Roberta Mussinelli, Silvia Mangiacavalli, Claudio Salvatore Cartia, Valeria Masoni, Michele Palumbo, Lorenzo Cani, Stefania Oliva, Ugo Consoli, Concetta Conticello, Francesco Di Raimondo, Luca Arcaini, Sara Bringhen, Giampaolo Merlini, Giovanni Palladini, Paolo Milani
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis. Hematological oncology 42 (4) (2024)
Claudia Bellofiore, Pietro Benvenuti, Roberto Mina, Marco Basset, Andrea Foli, Martina Nanci, Mario Nuvolone, Gianluigi Guida, Andrea Attanasio, Roberta Mussinelli, Silvia Mangiacavalli, Claudio Salvatore Cartia, Valeria Masoni, Michele Palumbo, Lorenzo Cani, Stefania Oliva, Ugo Consoli, Concetta Conticello, Francesco Di Raimondo, Luca Arcaini, Sara Bringhen, Giampaolo Merlini, Giovanni Palladini, Paolo Milani
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis. Hematological oncology 42 (4) (2024)

volume 42, number 5, 2024

Marie Anne-Catherine Neumann, Jan-Hendrik Naendrup, Jorge Garcia Borrega, Ismini Halmer, Lisa Altenrath, Noelle Sieg, Michael Hallek, Dennis A Eichenauer, Jan-Michel Heger
Characteristics, outcomes and health care utilization of patients with acute myeloid leukemia aged 70 years or older: A single-center retrospective analysis. Hematological oncology 42 (5) (2024)
Beatrice Casadei, Gabriele Conti, Monica Barone, Silvia Turroni, Serafina Guadagnuolo, Alessandro Broccoli, Patrizia Brigidi, Lisa Argnani, Pier Luigi Luigi Zinzani
Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors-The MicroLinf Study. Hematological oncology 42 (5) (2024)
Taku Kikuchi, Yuki Oda, Ukyo Kondo, Nobuhiro Tsukada, Kodai Kunisada, Chiaki Matsumoto, Moe Nomura-Yogo, Kota Sato, Tomomi Takei, Mizuki Ogura, Yu Abe, Kenshi Suzuki, Osamu Hosoya, Tadao Ishida
Prognostic value of the "dynamic" R2-ISS in patients with multiple myeloma undergoing anti-CD38 antibody-based triplet therapies. Hematological oncology 42 (5) (2024)
Shyam Srinivasan
From trials to statistical insights: Bortezomib's story in childhood T-cell lymphoid malignancies. Hematological oncology 42 (5) (2024)
Nicola Polverelli, M Anghilieri, C Elena, T Intermesoli, E Pungolino, M D'Adda, Alessandra Iurlo, M Maffioli, F Lunghi, V Bertolli, N Orofino, C Sissa, C Fiamenghi, A Gardellini, M Ubezio, M C Carraro, P Corradini, F Giglio, M C Pasquini, R Palazzolo, R Calori, M Ercolanoni, Carlo B Gambacorti-Passerini
Direct determination of chronic myeloid leukemia prevalence in Lombardy-Italy: Global implications. Hematological oncology 42 (5) (2024)
Taku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, Chiaki Matsumoto, Moe Nomura-Yogo, Yuki Oda, Kota Sato, Tomomi Takei, Mizuki Ogura, Yu Abe, Kenshi Suzuki, Osamu Hosoya, Tadao Ishida
Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real-world clinical setting. Hematological oncology 42 (5) (2024)
Evgenia Verrou, Sotirios G Papageorgiou, Maria Bouzani, Aggeliki Sevastoudi, Theodora Triantafyllou, Aikaterini Daiou, Dimitra Dalampira, Maria Arapaki, Chara Giatra, Anastasia Banti, Gerasimos Kyriakidis, Dionisios Stoumpos, Nikolaos Karampatzakis, Theodosia Papadopoulou, Maria Kotsopoulou, Anastasia Pouli, Evdokia Mandala, Vassiliki Pappa, Emmanouil Spanoudakis, Eirini Katodritou, Theodoros P Vassilakopoulos
Clinical characteristics and outcome of early-stage diffuse large B cell lymphoma of female genital track: A retrospective study of the Hellenic cooperative lymphoma group. Hematological oncology 42 (5) (2024)
Taku Kikuchi, Yuki Oda, Ukyo Kondo, Nobuhiro Tsukada, Kodai Kunisada, Chiaki Matsumoto, Moe Nomura-Yogo, Kota Sato, Tomomi Takei, Mizuki Ogura, Yu Abe, Kenshi Suzuki, Osamu Hosoya, Tadao Ishida
Prognostic value of the "dynamic" R2-ISS in patients with multiple myeloma undergoing anti-CD38 antibody-based triplet therapies. Hematological oncology 42 (5) (2024)
Mohammed Zuber, Samruddhi Nandkumar Borate, Pooja Gokhale, Akhila Yerubandi, N M Mahmudul Alam Bhuiya, Smita Rawal, Henry N Young, Lorenzo Villa Zapata
Bruton tyrosine kinase inhibitor monotherapy in B-cell lymphoma and risk of infection: A systematic review and meta-analysis of randomized controlled trials. Hematological oncology 42 (5) (2024)
Yan Han, Chuntuan Li, Shengquan Liu, Jingjing Gao, Yanjun He, Huifang Xiao, Qi Chen, Yan Zheng, Hongyuan Chen, Xiongpeng Zhu
Combined targeting of Hedgehog/GLI1 and Wnt/β-catenin pathways in mantle cell lymphoma. Hematological oncology 42 (5) (2024)
Maria Carmen Martinez Munoz, Esther Carcelero, Antonio Gutiérrez, Esther Sancho, Josep Maria Martí-Tutusaus, Laura Magnano, Pablo Mozas, Francesc Fernández-Avilés, María Gabriela Antelo, Xavier Setoain, Sonia Rodríguez, Jordi Esteve
Efficacy of escalating therapy with brentuximab vedotin-AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD. Hematological oncology 42 (5) (2024)
Daniele Cattaneo, Cristina Bucelli, Valentina Bellani, Barbara Mora, Alessandra Iurlo
Treatment-free remission as a new goal in the management of chronic myeloid leukemia: Clinical and biological aspects. Hematological oncology 42 (5) (2024)
Fang He, Yan Tu, Lihong Ni
Research on the mechanism of HOPX-HDAC2 interaction inducing differentiation blockage in acute myeloid leukemia. Hematological oncology 42 (5) (2024)
Stefano Cordella, Davide Giusti, Eleonora De Bellis, Michelina Dargenio, Federica Creti', Davide Lazzarotto, Chiara Cattaneo, Nicola Stefano Fracchiolla, Matteo Piccini, Fabio Forghieri, Livio Pagano, Anna Candoni
Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax. Hematological oncology 42 (5) (2024)